Improved growth with growth hormone therapy in a child with glycogen storage disease Ib

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 8, 2003, Pages 977-979

  Noto, Richard A ^a   Vijayaraghavan, V ^b   Timoshin, A ^a   Sansobrino, D ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

Follicle stimulating hormone (FSH); Glycogen storage disease (GSD); Growth hormone (GH); Inflammatory bowel disease (IBD); Insulin like growth factor I (IGF 1); Luteinizing hormone (LH); Thyroid stimulating hormone (TSH)

Indexed keywords

CHOLESTEROL; CITRATE POTASSIUM; CLONIDINE; GROWTH HORMONE; MESALAZINE; POTASSIUM CHLORIDE; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; GENERAL CONDITION IMPROVEMENT; GLYCOGEN STORAGE DISEASE TYPE 1; GROWTH RATE; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; METABOLISM; PRIORITY JOURNAL; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

ADOLESCENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE I; GROWTH; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS;

EID: 0042876957     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250310004234     Document Type: Article

References (15)

1. Collu R, Ducharme JR, Guyda HJ. Pediatric Endocrinology. New York: Raven Press; 1989: 658-60
2. Kelley WN, Rosenbloom FM, Seegmiller JE, Howell RR. Excessive production of uric acid in type I glycogen storage disease. J Pediatr 1968; 72: 488-96
3. Greene HL, Slonim AE, Burr IM, Moran JR. Type I glycogen storage disease: five years of management with nocturnal intragastric feeding. J Pediatr 1980; 96: 590-5
4. Chen Y, Cornblath M, Sidbury J. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984; 310: 171-5
5. Fine RN, Frasier SD, Donnell GN. Growth in glycogen-storage disease type I: evaluation of endocrine function. Am J Dis Child 1969; 117: 169-77
6. Larizza D, Maggiore G, Marzani D, Maghnie M, Ciceri R. Difficult hGH treatment in a patient with type III glycogen storage disease. Eur J Pediatr 1986; 145: 84-5
7. Greene HL, Swift LL, Knapp HR. Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. J Pediatr 1991; 119: 398-403
8. Tonstad S. Role of lipid-lowering pharmacotherapy in children. Pediatr Drugs 2000; 2: 11-22
9. Bierich JR. Serum growth hormone levels in provocation tests and during nocturnal spontaneous secretion: a comparative study. Acta Paediatr Scand 1987; 337: 48
10. Bierich JR. Growth hormone therapy in short children without classical growth hormone deficiency. J Endocrinol Invest 1989; 12: 25-33
11. Wolfsdorf JL, Diaz R, Kohane IS, Crigler JF. Growth and nocturnal growth hormone (GH) secretion in type I glycogen storage disease (GSD-1). Pediatr Res 1995; 37: 101A
12. Dunger DB, Holder AT, Leonard JV, Okae J, Preece MA. Growth and endocrine changes in the hepatic glycogenoses. Eur J Pediatr 1982; 138: 226-30
13. Nuoffer JM, Mullis PE, Wiesmann UN. Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth. J Inher Metab Dis 1997: 790-8
14. Lockwood DH, Merimee TJ, Edgar PJ, Greene ML, Fujimoto WY, Seegmiller JE, et al. Insulin secretion in type I glycogen storage disease. Diabetes 1969; 18: 755-8
15. Okada S, Seino Y, Kodama H, Yutaka T, Inui K, Ishida M, et al. Insulin and glucagon secretion in hepatic glycogenoses. Acta Paediatr Scand 1979; 68: 735-8